WARPTECHNEWS · LAB

Home AI Business Tech Archive

WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

Home
Archivio
Editor's Brief
Cerca
Il tuo account
Newsletter tech/AI

Informazioni legali

Privacy Policy
Termini di servizio
Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Storia in 10 fonti

AstraZeneca, Ionis report major trial failure with heart disease drug

AstraZeneca and Ionis reported a notable trial failure Thursday in a heart disease that's become an increasingly competitive market for drugmakers.

Raccontata da

biopharmadive.com

thehindubusinessline.com

economictimes.indiatimes.com

independent.co.uk

fiercepharma.com

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

statnews.comStai leggendo1 g fa

AstraZeneca, Ionis report major trial failure with heart disease drug

AstraZeneca and Ionis reported a notable trial failure Thursday in a heart disease that's become an increasingly competitive market for drugmakers.

Timeline cronologica

giovedì 9 luglio 2026·biopharmadive.com
AstraZeneca, Ionis drug fails big heart disease study in major setback
Eplontersen’s failure in transthyretin-mediated amyloidosis cardiomyopathy caught Wall Street analysts by surprise and boosted the outlook of rival drugs from Alnylam and…
giovedì 9 luglio 2026·cnbc.com
AstraZeneca stock dives 9% after heart drug trial misses target
A late-stage clinical trial failed to miss its primary endpoint, U.K.'s laregst drugmaker said Thursday.

1 g fa

AstraZeneca sinks on unexpected heart drug trial failure

AstraZeneca shares sink up to 9% after Wainua misses cardiovascular endpoint in Phase 3 ATTR-CM trial with partner Ionis.

Leggi questa versione → originale

biopharmadive.com2 g fa

AstraZeneca, Ionis drug fails big heart disease study in major setback

Eplontersen’s failure in transthyretin-mediated amyloidosis cardiomyopathy caught Wall Street analysts by surprise and boosted the outlook of rival drugs from Alnylam and BridgeBio Pharma.

Leggi questa versione → originale

AstraZeneca stock dives 9% after heart drug trial misses target

A late-stage clinical trial failed to miss its primary endpoint, U.K.'s laregst drugmaker said Thursday.

Leggi questa versione → originale

fiercepharma.com1 g fa

AZ, Ionis shares tumble on ATTR-CM trial flop, but analyst flags over-reaction

The surprising failure of AstraZeneca and Ionis in a key phase 3 tria | The surprising failure of AstraZeneca and Ionis in a key phase 3 trial of Wainua in patients with ATTR-CM has sent the companies' shares tumbling,…

Leggi questa versione → originale

irishtimes.com1 g fa

AstraZeneca shares slide 9% after heart treatment disappoints in trial

UK pharmaceutical company said Wainua drug did not meet goal of reducing cardiovascular deaths

Leggi questa versione → originale

giovedì 9 luglio 2026·

thehindubusinessline.com

AstraZeneca’s Wainua fails main goal in late-stage heart disease trial

Drug developed with Ionis could not reduce cardiovascular deaths or recurring heart problems

giovedì 9 luglio 2026·

endpoints.news

AstraZeneca sinks on unexpected heart drug trial failure

AstraZeneca shares sink up to 9% after Wainua misses cardiovascular endpoint in Phase 3 ATTR-CM trial with partner Ionis.

giovedì 9 luglio 2026·

economictimes.indiatimes.com

AstraZeneca shares slide after Ionis-partnered drug fails late-stage heart disease trial

AstraZeneca shares fell after Wainua failed a key trial. The drug did not reduce cardiovascular deaths or heart problems. Wainua showed no effect in patients already on stabilizer…

giovedì 9 luglio 2026·

statnews.com

AstraZeneca, Ionis report major trial failure with heart disease drug

AstraZeneca and Ionis reported a notable trial failure Thursday in a heart disease that's become an increasingly competitive market for drugmakers.

giovedì 9 luglio 2026·

independent.co.uk

AstraZeneca sees stock market value slump by more than £20bn after drug setback

The FTSE 100 firm found the Wainua drug failed to meet a goal to reduce deaths related to heart disease.

giovedì 9 luglio 2026·

benzinga.com

Why Is Ionis Pharmaceuticals, AstraZeneca Stock Tumbling Today? - AstraZeneca (NYSE:AZN), Ionis Pharmaceu

Ionis and AstraZeneca said Phase 3 eplontersen missed its primary ATTR-CM endpoint, while secondary measures and safety remained favorable.

giovedì 9 luglio 2026·

irishtimes.com

AstraZeneca shares slide 9% after heart treatment disappoints in trial

UK pharmaceutical company said Wainua drug did not meet goal of reducing cardiovascular deaths

giovedì 9 luglio 2026·

fiercepharma.com

AZ, Ionis shares tumble on ATTR-CM trial flop, but analyst flags over-reaction

The surprising failure of AstraZeneca and Ionis in a key phase 3 tria | The surprising failure of AstraZeneca and Ionis in a key phase 3 trial of Wainua in patients with ATTR-CM…

venerdì 10 luglio 2026·

benzinga.com

Ionis, AstraZeneca Stumble in ATTR-CM Trial as Rivals Stand to Gain - Ionis Pharmaceuticals (NASDAQ:IONS)

Ionis and AstraZeneca's Phase 3 ATTR-CM trial misses its primary goal, analyst says the outcome favors existing and next-gen therapies.